Latest Breaking News On - Remi barbier - Page 1 : comparemela.com

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRemi barbierEric schoenCassava sciencesExchange commissionCapital advisorsChief financialNew york cityAny warrantsYork cityRedemption priceCall warrants

Cassava Sciences (SAVA) Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences (SAVA) Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Puerto ricoSouth koreaRemi barbierCassava sciencesCassava sciences incResearch internationalSafety monitoring boardCassava sciencePremier research international

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery.

Remi barbierMichael marsmanLindsayh burnsMichael zamlootChris cookJim kupiecEric schoenRegulatory affairsIntroduction to cassava sciencesCassava sciencesNational institutes of healthDiscovery development programCorporate overview first quarterAnnual reportPrivate securities litigation reform actNational institutes

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials.

United statesPuerto ricoSouth koreaEric schoenRemi barbierCassava sciencesResearch internationalCassava sciences incSafety monitoring boardRecently evaluatedInterim patient safety databaseOral simufilamOn going phaseBoth phaseClinical safety dataSimufilam are expected

Cassava Sciences Reports Full-year 2023 Financial Results

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over.

United statesPuerto ricoSouth koreaNew yorkPierre gravierRemi barbierEric schoenRobert anderson jrCassava sciences incCochin institute parisCity university of new yorkDrug administrationOrrick herrington sutcliffeCassava sciencesCompany board of directorsResearch international